{
    "clinical_study": {
        "@rank": "123",
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on April 06, 2020",
            "link_text": "Link to the current ClinicalTrials.gov record.",
            "url": "https://clinicaltrials.gov/show/NCT04326790"
        },
        "id_info": {
            "org_study_id": "906295542",
            "nct_id": "NCT04326790"
        },
        "brief_title": "The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention",
        "acronym": "GRECCO-19",
        "official_title": "The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention",
        "sponsors": {
            "lead_sponsor": {
                "agency": "National and Kapodistrian University of Athens",
                "agency_class": "Other"
            }
        },
        "source": "National and Kapodistrian University of Athens",
        "oversight_info": {
            "has_dmc": "Yes",
            "is_fda_regulated_drug": "No",
            "is_fda_regulated_device": "No"
        },
        "brief_summary": {
            "textblock": "Based on data regarding the effect of colchicine on the inflammasome NLP3 and microtubule\n      formation and associations thereof with the pathogenetic cycle of SARS-COV-2, the question\n      arises whether colchicine, administered in a relatively low dose, could potentially have an\n      effect the patients' clinical course by limiting the myocardial necrosis and pneumonia\n      development in the context of COVID-19. If present, this effect would be attributed to its\n      potential to inhibit inflammasome and (less probably) to the process of SARS-CoV-2\n      endocytosis in myocardial and endothelial respiratory cells."
        },
        "overall_status": "Not yet recruiting",
        "start_date": {
            "@type": "Anticipated",
            "#text": "April 6, 2020"
        },
        "completion_date": {
            "@type": "Anticipated",
            "#text": "September 30, 2020"
        },
        "primary_completion_date": {
            "@type": "Anticipated",
            "#text": "August 31, 2020"
        },
        "phase": "Phase 2",
        "study_type": "Interventional",
        "has_expanded_access": "No",
        "study_design_info": {
            "allocation": "Randomized",
            "intervention_model": "Parallel Assignment",
            "intervention_model_description": "Patient-level randomization scheme",
            "primary_purpose": "Treatment",
            "masking": "None (Open Label)"
        },
        "primary_outcome": [
            {
                "measure": "CRP increase to 3 x upper limit of normal",
                "time_frame": "3 weeks",
                "description": "Time to increase in C-reactive protein to 3 times the ULN"
            },
            {
                "measure": "Clinical deterioration in the semiquantitative ordinal scale suggested by the WHO R&D committee",
                "time_frame": "3 weeks",
                "description": "Time to clinical deterioration (2 levels in the WHO R&D Blueprint scale)"
            },
            {
                "measure": "Maximal concentration of cardiac troponin",
                "time_frame": "10 days",
                "description": "Maximal concentration of high-sensitivity cardiac troponin"
            }
        ],
        "number_of_arms": "2",
        "enrollment": {
            "@type": "Anticipated",
            "#text": "180"
        },
        "condition": "Corona Virus Disease 19 (Covid 19)",
        "arm_group": [
            {
                "arm_group_label": "Intervention",
                "arm_group_type": "Experimental",
                "description": "Colchicine, on top of standard treatment"
            },
            {
                "arm_group_label": "Control",
                "arm_group_type": "Active Comparator",
                "description": "Standard treatment, including all medications recommedned by the National Public Health Organization"
            }
        ],
        "intervention": [
            {
                "intervention_type": "Drug",
                "intervention_name": "Colchicine",
                "description": "Low-dose colchicine treatment, 0.5 mg bid",
                "arm_group_label": "Intervention"
            },
            {
                "intervention_type": "Drug",
                "intervention_name": "Standard treatment",
                "description": "Standard treatment",
                "arm_group_label": [
                    "Control",
                    "Intervention"
                ]
            }
        ],
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patients >18 years old with laboratory confirmed SARS-CoV-2 infection (RT PCR) AND body\n        temperature >37.5 degrees centigrade AND at least two of: i. sustained coughing, ii.\n        sustained throat pain, iii. anosmia and/or ageusia, iv. fatigue/tiredness, v. PaO2<95 mmHg.\n\n        Exclusion Criteria:\n\n          -  pregnancy, lactation;\n\n          -  known hypersensitivity to colchicine\n\n          -  known hepatic failure\n\n          -  eGFR<20 ml/min\n\n          -  clinical estimation that the patient will require mechanical respiratory support in\n             less than 24 hours\n\n          -  any clinical estimation of the attending physician under which the patient shall be\n             excluded\n\n          -  QTc > 450 msec (colchicine is not known to significantly prolong QTc, but may interact\n             with other medications which prolong QTc).\n\n          -  participation in another clinical trial\n\n          -  under colchicine treatment for other indications\n\n          -  patient who is not likely to comply to study procedures"
            },
            "gender": "All",
            "minimum_age": "18 Years",
            "maximum_age": "N/A",
            "healthy_volunteers": "No"
        },
        "overall_contact": {
            "last_name": "Spyridon Deftereos",
            "phone": "00306944699901",
            "email": "spdeftereos@gmail.com"
        },
        "verification_date": "March 2020",
        "study_first_submitted": "March 26, 2020",
        "study_first_submitted_qc": "March 26, 2020",
        "study_first_posted": {
            "@type": "Actual",
            "#text": "March 30, 2020"
        },
        "last_update_submitted": "March 31, 2020",
        "last_update_submitted_qc": "March 31, 2020",
        "last_update_posted": {
            "@type": "Actual",
            "#text": "April 2, 2020"
        },
        "responsible_party": {
            "responsible_party_type": "Principal Investigator",
            "investigator_affiliation": "National and Kapodistrian University of Athens",
            "investigator_full_name": "Spyridon Deftereos",
            "investigator_title": "Professor of Cardiology"
        },
        "condition_browse": {
            "mesh_term": [
                "Coronavirus Infections",
                "Virus Diseases"
            ]
        },
        "intervention_browse": {
            "mesh_term": "Colchicine"
        },
        "patient_data": {
            "sharing_ipd": "Undecided"
        }
    }
}